Dapagliflozin transfer in breast milk may be clinically insignificant—An opportunity for optimization of evidence‐based management of heart failure in postpartum patients
Pregnancy · 2026-11 · 2 (6)
DOI: 10.1002/pmf2.70500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pregnancy, online erschienen am 14.11.2026. Verfasst von Ashley Bartell und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology Division of Maternal-Fetal Medicine University of Michigan Ann Arbor Michigan USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Dapagliflozin (DAPA), a sodium‐glucose co‐transporter inhibitor (SGLT2i), has been shown to prevent the development of heart failure and slow the progression of pre‐existing heart failure; however, there are limited data published to demonstrate the safety of postpartum lactating individuals taking SGLT2is.
Methods
Lactating patients received two oral doses of 10 mg DAPA over a 48‐h period. Breast milk and plasma were collected 2 h after the second dose. Samples were processed via liquid chromatography mass spectrometry (LCMS) analysis. Breast milk concentrations of DAPA were divided by plasma concentrations of DAPA (in ng/mL). The absolute (AID; i.e., daily infant dose) and relative infant doses (RID) were performed. An RID of 10% was considered the limit of acceptable exposure.
Results
Three of four participants were able to produce enough sample for assessment. Across three samples, the mean DAPA concentrations in plasma and breast milk were 77.6 ± 10.2 and 16.8 ± 3.1 ng/mL, respectively. Mean AID was 8.04 × 10 −3 ± 2.50 × 10 −3 mg/day and the mean RID was 7.73 ± 3.9%.
Conclusions
This study demonstrates that human breast milk collected at peak anticipated maternal concentrations of DAPA has a mean RID below 10%. This is the first report of human transfer levels for DAPA, generating preliminary lactation‐specific pharmacokinetic data that are essential to support evidence‐based treatment of breastfeeding individuals and reduce disparities in their representation within cardiovascular therapeutic research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology Division of Maternal-Fetal Medicine University of Michigan Ann Arbor Michigan USA.
- Department of Obstetrics and Gynecology Division of Maternal-Fetal Medicine Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA.
- Department of Pediatrics Division of Endocrinology University of Michigan Ann Arbor Michigan USA.
- Department of Nutritional Sciences School of Public Health University of Michigan Ann Arbor Michigan USA.
Zitieren
APA
Bartell, A., Erickson, J., Anderson, L. J., Boitos, L., Katzman, H. R., Mohamed, M., Dwyer, S., Tumbarello, J., Kirschen, G. W., Langen, E., Grabowski, A., & Gregg, B. (2026). Dapagliflozin transfer in breast milk may be clinically insignificant—An opportunity for optimization of evidence‐based management of heart failure in postpartum patients. Pregnancy, 2(6). https://doi.org/10.1002/pmf2.70500
Vancouver
Bartell A, Erickson J, Anderson LJ, Boitos L, Katzman HR, Mohamed M, et al. Dapagliflozin transfer in breast milk may be clinically insignificant—An opportunity for optimization of evidence‐based management of heart failure in postpartum patients. Pregnancy. 2026;2(6). doi:10.1002/pmf2.70500
BibTeX
@article{Bartell2026,
author = {Bartell, Ashley and Erickson, Julia and Anderson, Levi J and Boitos, Laine and Katzman, Hadley R and Mohamed, Munira and Dwyer, Sarah and Tumbarello, Julie and Kirschen, Gregory W and Langen, Elizabeth and Grabowski, Aria and Gregg, Brigid},
title = {Dapagliflozin transfer in breast milk may be clinically insignificant—An opportunity for optimization of evidence‐based management of heart failure in postpartum patients},
journal = {Pregnancy},
year = {2026},
volume = {2},
number = {6},
doi = {10.1002/pmf2.70500}
}
EUVIMED